Novartis (NYSENVS) Entresto (sacubitril / valsartan) for the treatment of adults with symptomatic chronic heart failure along with diminished ejection fraction (HFrEF). Essay

Novartis' (NYSENVS) Entresto (sacubitril/valsartan) gets the approval for the treatment and management in adults suffering from symptomatic chronic heart failure along with diminished ejection fraction (HFrEF). Entresto is a twice a day dosage formulation. It has a very unique action, which is thought to reduce burden and strain on failing heart.
Entresto is main option for the treatment of heart failure with reduced ejection fraction.
Novartis get this approval totally based on the scientific data and evidence from the 8,442patient PARADIGMHF study in patients suffering from HFrEF. The study was stopped earlier as Entresto significantly reduced the risk of death related to cardiovascular cause versus enalapril. As per the clinical data, the patients treated with Entresto were alive and stable. They have very less hospital visits or ER visits for heart failure as compared to those who were on enalapril. Safety profile analysis based on scientific data proved Entresto having the same tolerability profile to enalapril.
Heart failure is a lifethreatening condition in which the heart becomes weak and is not able to pump enough quantity of blood. The cardiac muscles get weak and stiff and make it nearly impossible for heart to pump blood. As a result of which patient is single step away from death. The patients need repeated hospitalizations. Majority of the patients suffers from symptoms such as fluid retention, breathlessness, and fatigue. These symptoms significantly affect the quality of life .
The number of patients is increasing day by day in Europe. Around 10,000 Europeans enter in the category of heart failure with an estimated 15 million people already spending their lives with the condition. It is really amazing to say that despite huge number of prevalence, majority of the population is unable to recognize the symptoms of heart failure. Majority of them are misdiagnosed giving the disease a chance to excel.
Entresto got approval by EU in September. Before approval, it is available in England via the MHRAs Early Access to Medicines Scheme. This scheme was started in March 2015. The main purpose of this scheme is to give access to the patient to get new promising new drugs, which are undergoing licensing.
Now as the drug is approved by EU, no patient will be able to get the Entresto treatment. As per the Novartis, they are planning to launch the drug in UK market before the end of 2015.
Dimitrios Georgiopoulos, chief scientific officer at Novartis Pharmaceuticals UK Heart failure is a lifethreatening condition that leaves a major impact on patients and their carers. There is a true need for new and potential treatments that can minimize mortality and morbidity as well as improving patients quality of life.
About Entresto
The mechanism of action is of any Angiotensin Receptor Neprilysin Inhibitor. The main function is to reduce the strain and stress on failing heart.
As far as side effect profile of Entresto is concerned, it includes largely hypotension and nonserious angioedema, but lesser extent of renal impairment, hyperkalemia, and cough as compared to enalapril group.